Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction

European Journal of Heart Failure

Volumn 16, Issue 9, 2014, Pages 958-966

  Lok, Dirk J ^a,b   Klip, IJsbrand T ^a   Voors, Adriaan A ^a   Lok, Sjoukje I ^c   Bruggink André De La Porte, Pieta W ^b   Hillege, Hans L ^a   Jaarsma, Tiny ^d   Van Veldhuisen, Dirk J ^a   Van Der Meer, Peter ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b DEVENTER HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Chronic heart failure; HFpEF; Natriuretic peptides; NT proCNP; Prognosis

Indexed keywords

BIOLOGICAL MARKER; NATRIURETIC PEPTIDE TYPE C; VASCULOTROPIN;

AGED; ARTICLE; CLINICAL EVALUATION; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL PATIENT; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SURVIVAL RATE; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGY; HEART STROKE VOLUME; MULTICENTER STUDY; NETHERLANDS; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TRENDS;

AGED; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMANS; INPATIENTS; MALE; NATRIURETIC PEPTIDE, C-TYPE; NETHERLANDS; PROGNOSIS; STROKE VOLUME; SURVIVAL RATE;

EID: 84908239933     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.140     Document Type: Article

References (45)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, MoulinC, Reiner Z, SechtemU, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-869.
2. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): A new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990;168:863-870.
3. Totsune K, Takahashi K, Murakami O, Satoh F, Sone M, Saito T, Sasano H, Mouri T, Abe K. Natriuretic peptides in the human kidney. Hypertension 1994;24:758-762.
4. Griffith TM. Endothelium-dependent smooth muscle hyperpolarization: do gap junctions provide a unifying hypothesis? Br J Pharmacol 2004;141:881-903.
5. Del Ry S, Maltinti M, Piacenti M, Passino C, Emdin M, Giannessi D. Cardiac production of C-type natriuretic peptide in heart failure. J Cardiovasc Med (Hagerstown) 2006;7:397-399.
6. Kalra PR, Clague JR, Bolger AP, Anker SD, Poole-Wilson PA, Struthers AD, Coats AJ. Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation 2003;107:571-573.
7. Barton M, Beny JL, d'Uscio LV, Wyss T, Noll G, Luscher TF. Endothelium-independent relaxation and hyperpolarization to C-type natriuretic peptide in porcine coronary arteries. J Cardiovasc Pharmacol 1998;31:377-383.
8. DelRy S, Cabiati M, Vozzi F, Battolla B, Caselli C, Forini F, Segnani C, Prescimone T, Giannessi D, Mattii L. Expression of C-type natriuretic peptide and its receptor NPR-B in cardiomyocytes. Peptides 2011;32:1713-1718.
9. Scotland RS, Ahluwalia A, Hobbs AJ. C-type natriuretic peptide in vascular physiology and disease. Pharmacol Ther 2005;105:85-93.
10. Wei CM, Heublein DM, Perrella MA, Lerman A, Rodeheffer RJ, McGregor CG, Edwards WD, Schaff HV, Burnett JC Jr. Natriuretic peptide system in human heart failure. Circulation 1993;88:1004-1009.
11. Prickett TC, Yandle TG, Nicholls MG, Espiner EA, Richards AM. Identification of amino-terminal pro-C-type natriuretic peptide in human plasma. Biochem Biophys Res Commun 2001;286:513-517.
12. Prickett TC, Olney RC, Cameron VA, Ellis MJ, Richards AM, Espiner EA. Impact of age, phenotype and cardio-renal function on plasma C-type and B-type natriuretic peptide forms in an adult population. Clin Endocrinol (Oxf) 2013;78:783-789.
13. DelRy S, Cabiati M, Stefano T, Catapano G, Caselli C, Prescimone T, Passino C, Emdin M, Giannessi D. Comparison of NT-proCNP and CNP plasma levels in heart failure, diabetes and cirrhosis patients. Regul Pept 2011;166: 15-20.
14. Jaarsma T, VanDerWal MH, Hogenhuis J, Lesman I, Luttik ML, Veeger NJ, Van Veldhuisen DJ. Design and methodology of the COACH study: A multicenter randomised Coordinating study evaluatingOutcomes of Advising and Counselling in Heart failure. Eur J Heart Fail 2004;6:227-233.
15. Jaarsma T, vanderWal MH, Lesman-Leegte I, Luttik ML, Hogenhuis J, Veeger NJ, Sanderman R, Hoes AW, vanGilst WH, Lok DJ, Dunselman PH, Tijssen JG, Hillege HL, vanVeldhuisen DJ, Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) Investigators. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med 2008;168:316-324.
16. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, vanVeldhuisen DJ. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43:60-68.
17. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003;362:777-781.
18. van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, Paulus WJ, Voors AA, Hillege HL. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013;61:1498-1506.
19. Kleijn L, Belonje AM, Voors AA, De Boer RA, Jaarsma T, Ghosh S, Kim J, Hillege HL, Van Gilst WH, van Veldhuisen DJ, van der Meer P. Inflammation and anaemia in a broad spectrum of patients with heart failure. Heart 2012;98:1237-1241.
20. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006;114:1572-1580.
21. Postmus D, van Veldhuisen DJ, Jaarsma T, Luttik ML, Lassus J, Mebazaa A, Nieminen MS, Harjola VP, Lewsey J, Buskens E, Hillege HL. The COACH risk engine: A multistate model for predicting survival and hospitalization in patients with heart failure. Eur J Heart Fail 2012;14:168-175.
22. Pencina MJ, D'Agostino RBS, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
23. Jeevanantham V, Shrivastava R, Nannapaneni S, Khan A, Sengodan M, Nautiyal A, Navaneethan S, Hsi D. Elevated B-type natriuretic peptide level: use with caution in patients with multiple co-morbidities and presenting with dyspnea. Indian Heart J 2007;59:64-68.
24. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-2550.
25. Alexandrakis MG, Tsirakis G. Anemia in heart failure patients. ISRN Hematol 2012;2012:246915.
26. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260-269.
27. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-259.
28. Davidson NC, Barr CS, Struthers AD. C-type natriuretic peptide. An endogenous inhibitor of vascular angiotensin-converting enzyme activity. Circulation 1996;93:1155-1159.
29. Stingo AJ, Clavell AL, Aarhus LL, Burnett JC Jr. Cardiovascular and renal actions of C-type natriuretic peptide. Am J Physiol 1992;262:H308-H312.
30. Arakawa H, Ikeda U, Hojo Y, Ueno S, Nonaka-Sarukawa M, Yamamoto K, Shimada K. Decreased serum vascular endothelial growth factor concentrations in patients with congestive heart failure. Heart 2003;89:207-208.
31. Zachariah JP, Xanthakis V, Larson MG, Vita JA, Sullivan LM, Smith HM, Safa R, Peng X, Hamburg N, Levy D, Sawyer DB, Mitchell GF, Vasan RS. Circulating vascular growth factors and central hemodynamic load in the community. Hypertension 2012;59:773-779.
32. De Boer RA, Pinto YM, Van Veldhuisen DJ. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: The role of microvascular growth and abnormalities. Microcirculation 2003;10:113-126.
33. Del Ry S, Cabiati M, Martino A, Cavallini C, Caselli C, Aquaro GD, Battolla B, Prescimone T, Giannessi D, Mattii L, Lionetti V. High concentration of C-type natriuretic peptide promotes VEGF-dependent vasculogenesis in the remodeled region of infarcted swine heart with preserved left ventricular ejection fraction. Int J Cardiol 2013;168:2426-2434.
34. Del Ry S, Passino C, Maltinti M, Emdin M, Giannessi D. C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity. Eur J Heart Fail 2005;7:1145-1148.
35. Wright SP, Prickett TC, Doughty RN, Frampton C, Gamble GD, Yandle TG, Sharpe N, Richards M. Amino-terminal pro-C-type natriuretic peptide in heart failure. Hypertension 2004;43:94-100.
36. Garcha RS, Hughes AD. CNP, but not ANP or BNP, relax human isolated subcutaneous resistance arteries by an action involving cyclic GMP and BKCa channels. J Renin Angiotensin Aldosterone Syst 2006;7:87-91.
37. Izumiya Y, Araki S, Usuku H, Rokutanda T, Hanatani S, Ogawa H. Chronic C-type natriuretic peptide infusion attenuates angiotensin II-induced myocardial superoxide production and cardiac remodeling. Int J Vasc Med 2012;2012:246058.
38. Soeki T, Kishimoto I, Okumura H, Tokudome T, Horio T, Mori K, Kangawa K. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol 2005;45:608-616.
39. Hobbs A, Foster P, Prescott C, Scotland R, Ahluwalia A. Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide. Circulation 2004;110:1231-1235.
40. Sangaralingham SJ, Huntley BK, Martin FL, McKie PM, Bellavia D, Ichiki T, Harders GE, Chen HH, Burnett JC Jr. The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic peptide. Hypertension 2011;57: 201-207.
41. Cabiati M, Raucci S, Liistro T, Belcastro E, Prescimone T, Caselli C, Matteucci M, Iozzo P, Mattii L, Giannessi D, Del Ry S. Impact of obesity on the expression profile of natriuretic peptide system in a rat experimental model. PLoS One 2013;8:e72959.
42. DelRy S, Maltinti M, Cabiati M, Emdin M, Giannessi D, Morales MA. C-type natriuretic peptide and its relation to non-invasive indices of left ventricular function in patients with chronic heart failure. Peptides 2008;29: 79-82.
43. Zakeri R, Sangaralingham SJ, Sandberg SM, Heublein DM, Scott CG, Burnett JC Jr. Urinary C-type natriuretic peptide: A new heart failure biomarker. JACC Heart Fail 2013;1:170-1877.
44. Phan TT, Abozguia K, Nallur Shivu G, Mahadevan G, Ahmed I, Williams L, Dwivedi G, Patel K, Steendijk P, Ashrafian H, Henning A, Frenneaux M. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol 2009;54:402-409.
45. Cotter G, Felker GM, Adams KF, Milo-Cotter O, O'Connor CM. The pathophysiology of acute heart failure-is it all about fluid accumulation? Am Heart J 2008;155:9-18.